Literature DB >> 9348195

Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.

C J Narvaez1, J Welsh.   

Abstract

1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), the active form of vitamin D3, and tetradecanoylphorbol acetate (TPA) are potent negative growth regulators of breast cancer cells. In this study, we compared the mechanism of action of these two compounds in MCF-7 cells and a vitamin D3-resistant variant (MCF-7D3Res). In parental MCF-7 cells, 1,25-(OH)2D3 induced morphological and biochemical markers of apoptosis (chromatin and nuclear matrix condensation and DNA fragmentation), whereas TPA induced growth arrest without apoptosis. Both 1,25-(OH)2D3 and TPA independently up-regulated the vitamin D receptor, p21, and the hypophosphorylated form of retinoblastoma (Rb) protein. The growth regulatory effects of 1,25-(OH)2D3 and TPA did not correlate with induction of p53 protein expression. When both compounds were added simultaneously, synergistic effects on MCF-7 cell number were observed, and cell cycle regulatory proteins were down-regulated. The MCF-7D3Res cells, which are not sensitive to 1,25-(OH)2D3, were growth inhibited by TPA, and TPA partially sensitized MCF-7D3Res cells to the growth inhibitory effects of 1,25-(OH)2D3. In MCF-7D3Res cells, 1,25-(OH)2D3 treatment had minimal effects on p21 or Rb protein expression, whereas TPA down-regulated Rb protein and transiently up-regulated p21. These studies indicate dissociation between the pathways triggered by 1,25-(OH)2D3 and TPA, which mediate growth regulation in MCF-7 cells. Because both compounds induce growth arrest, but only 1,25-(OH)2D3 mediates apoptosis, we conclude that cell cycle arrest is not sufficient to trigger cell death of MCF-7 cells, and that 1,25-(OH)2D3 generates distinct signals which lead to induction of apoptosis in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9348195     DOI: 10.1210/endo.138.11.5545

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.

Authors:  Belinda Byrne; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

3.  Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.

Authors:  Omar Flores; Zhengying Wang; Karen E Knudsen; Kerry L Burnstein
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

4.  Phosphorylation at serine 482 affects stability of NF90 and its functional role in mitosis.

Authors:  N L Smith; W K Miskimins
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

5.  Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.

Authors:  E Nolan; M Donepudi; K VanWeelden; L Flanagan; J Welsh
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

6.  Characterization of Vitamin D insensitive prostate cancer cells.

Authors:  Adebusola A Alagbala; Michael T Moser; Candace S Johnson; Donald L Trump; Barbara A Foster
Journal:  J Steroid Biochem Mol Biol       Date:  2007-02-05       Impact factor: 4.292

7.  BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer.

Authors:  Wei Xia; Satoru Nagase; Amy Gerstein Montia; Sergey M Kalachikov; Megan Keniry; Tao Su; Lorenzo Memeo; Hanina Hibshoosh; Ramon Parsons
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

Review 8.  Molecular actions of vitamin D contributing to cancer prevention.

Authors:  James C Fleet
Journal:  Mol Aspects Med       Date:  2008-08-08

9.  Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.

Authors:  Robert Wieder; Steven C Novick; Bruce W Hollis; Margarette Bryan; Suzanne M Chanel; Kate Owusu; Danielle Camastra; Tracie Saunders; Lillian Pliner; Jonathan Harrison; Peter Bonate; Tom Williams; Steven Soignet
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

10.  Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells.

Authors:  S S Larsen; I Heiberg; A E Lykkesfeldt
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.